

# Chemotherapy-induced Neutropenia Therapeutics Market Size, Trends, Analysis, and Outlook By Type (Antibiotic Therapy, Granulocyte Colony-Stimulating Factor Therapy, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), by Region, Country, Segment, and Companies, 2024-2030

<https://marketpublishers.com/r/C08C3FA7E66CEN.html>

Date: March 2024

Pages: 190

Price: US\$ 3,980.00 (Single User License)

ID: C08C3FA7E66CEN

## Abstracts

The global Chemotherapy-induced Neutropenia Therapeutics market size is poised to register 5.6% growth (CAGR) from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Chemotherapy-induced Neutropenia Therapeutics market By Type (Antibiotic Therapy, Granulocyte Colony-Stimulating Factor Therapy, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others).

The future of chemotherapy-induced neutropenia therapeutics is characterized by advancements in targeted therapies, supportive care interventions, and personalized treatment approaches aimed at reducing the risk of infection, enhancing immune recovery, and improving treatment outcomes for cancer patients undergoing chemotherapy. Key trends include the development of novel myeloid growth factors, such as granulocyte colony-stimulating factors (G-CSFs) and granulocyte-macrophage colony-stimulating factors (GM-CSFs), which stimulate white blood cell production and accelerate neutrophil recovery, reducing the duration and severity of neutropenia and its associated complications. Additionally, the integration of prophylactic antibiotic therapy, antifungal agents, and immunomodulatory drugs offers complementary strategies for preventing infectious complications and supporting immune function during periods of neutropenia, reducing the risk of treatment delays, dose reductions, and hospitalizations. Moreover, the customization of treatment regimens and supportive

care protocols based on patient-specific factors, such as chemotherapy regimen, disease type, and comorbidities, drives personalized approaches and optimization of neutropenia management, ensuring safe and effective treatment delivery while minimizing treatment-related toxicities and adverse events. Furthermore, the exploration of innovative treatment modalities, such as biosimilar G-CSFs, long-acting formulations, and oral agents, offers new opportunities for improving treatment convenience, patient adherence, and healthcare resource utilization in the management of chemotherapy-induced neutropenia. Overall, these advancements in neutropenia therapeutics offer cancer patients and healthcare providers effective tools for mitigating the hematologic toxicities of chemotherapy, enhancing treatment tolerability, and improving overall treatment outcomes..

### Chemotherapy-induced Neutropenia Therapeutics Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Chemotherapy-induced Neutropenia Therapeutics market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Chemotherapy-induced Neutropenia Therapeutics survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Chemotherapy-induced Neutropenia Therapeutics industry.

### Key market trends defining the global Chemotherapy-induced Neutropenia Therapeutics demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

### Chemotherapy-induced Neutropenia Therapeutics Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The Chemotherapy-induced Neutropenia Therapeutics industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future

revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Chemotherapy-induced Neutropenia Therapeutics companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Chemotherapy-induced Neutropenia Therapeutics industry

Leading Chemotherapy-induced Neutropenia Therapeutics companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Chemotherapy-induced Neutropenia Therapeutics companies.

Chemotherapy-induced Neutropenia Therapeutics Market Study- Strategic Analysis Review

The Chemotherapy-induced Neutropenia Therapeutics market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

**Industry Dynamics:** Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.

**Strategic Insights:** Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.

**Internal Strengths and Weaknesses:** Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.

**Future Possibilities:** Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

Chemotherapy-induced Neutropenia Therapeutics Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Chemotherapy-induced Neutropenia Therapeutics industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

## Chemotherapy-induced Neutropenia Therapeutics Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

## North America Chemotherapy-induced Neutropenia Therapeutics Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Chemotherapy-induced Neutropenia Therapeutics market segments. Similarly, Strong end-user demand is encouraging Canadian Chemotherapy-induced Neutropenia Therapeutics companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Chemotherapy-induced Neutropenia Therapeutics market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

## Europe Chemotherapy-induced Neutropenia Therapeutics Market Size Outlook- Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Chemotherapy-induced Neutropenia Therapeutics industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Chemotherapy-induced Neutropenia Therapeutics market for an

upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

**Asia Pacific Chemotherapy-induced Neutropenia Therapeutics Market Size Outlook- an attractive hub for opportunities for both local and global companies**

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Chemotherapy-induced Neutropenia Therapeutics in Asia Pacific. In particular, China, India, and South East Asian Chemotherapy-induced Neutropenia Therapeutics markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.

**Latin America Chemotherapy-induced Neutropenia Therapeutics Market Size Outlook- Continued urbanization and rising income levels**

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

**Middle East and Africa Chemotherapy-induced Neutropenia Therapeutics Market Size Outlook- continues its upward trajectory across segments**

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Chemotherapy-induced Neutropenia Therapeutics market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Chemotherapy-induced Neutropenia Therapeutics.

**Chemotherapy-induced Neutropenia Therapeutics Market Company Profiles**

The global Chemotherapy-induced Neutropenia Therapeutics market is characterized

by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are AbbVie Inc, Aurobindo Pharma, BeyondSpring Pharmaceuticals Inc, Coherus BioSciences, G1 Therapeutics Inc, GlaxoSmithKline PLC, Lupin, Merck & Co. Inc, Novartis AG, Spectrum Pharmaceuticals, Teva Pharmaceuticals Industries Ltd.

## Recent Chemotherapy-induced Neutropenia Therapeutics Market Developments

The global Chemotherapy-induced Neutropenia Therapeutics market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

## Chemotherapy-induced Neutropenia Therapeutics Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

## Qualitative Analysis

Pricing Analysis

Value Chain Analysis

SWOT Profile

Market Dynamics- Trends, Drivers, Challenges

Porter's Five Forces Analysis

Macroeconomic Impact Analysis

Case Scenarios- Low, Base, High

Market Segmentation:

By Type

Stationary 3D and 4D Ultrasound Devices

Portable 3D and 4D Ultrasound Devices

By Display

Color Ultrasound

B/W Ultrasound

By Portability

Trolley or Cart-Based Ultrasound Systems

Compact/Handheld Ultrasound Systems

Point-of-Pare (PoC) Ultrasound Systems

By Application

Radiology or General Imaging

Obstetrics or Gynecology

Cardiology

Urology

Vascular

Orthopedic and Musculoskeletal

Pain Management

Others



By End-User

Hospitals

Surgical Centers and Diagnostic Centers

Maternity Centers

Ambulatory Care Centers

Research and Academia

Others

Geographical Segmentation:

North America (3 markets)

Europe (6 markets)

Asia Pacific (6 markets)

Latin America (3 markets)

Middle East Africa (5 markets)

Companies

AbbVie Inc

Aurobindo Pharma

BeyondSpring Pharmaceuticals Inc

Coherus BioSciences

G1 Therapeutics Inc



GlaxoSmithKline PLC

Lupin

Merck & Co. Inc

Novartis AG

Spectrum Pharmaceuticals

Teva Pharmaceuticals Industries Ltd

Formats Available: Excel, PDF, and PPT

## Contents

### 1. EXECUTIVE SUMMARY

- 1.1 Chemotherapy induced Neutropenia Therapeutics Market Overview and Key Findings, 2024
- 1.2 Chemotherapy induced Neutropenia Therapeutics Market Size and Growth Outlook, 2021- 2030
- 1.3 Chemotherapy induced Neutropenia Therapeutics Market Growth Opportunities to 2030
- 1.4 Key Chemotherapy induced Neutropenia Therapeutics Market Trends and Challenges
  - 1.4.1 Chemotherapy induced Neutropenia Therapeutics Market Drivers and Trends
  - 1.4.2 Chemotherapy induced Neutropenia Therapeutics Market Challenges
- 1.5 Competitive Landscape and Key Players
- 1.6 Competitive Analysis- Growth Strategies Adopted by Leading Chemotherapy induced Neutropenia Therapeutics Companies

### 2. CHEMOTHERAPY INDUCED NEUTROPENIA THERAPEUTICS MARKET SIZE OUTLOOK TO 2030

- 2.1 Chemotherapy induced Neutropenia Therapeutics Market Size Outlook, USD Million, 2021- 2030
- 2.2 Chemotherapy induced Neutropenia Therapeutics Incremental Market Growth Outlook, %, 2021- 2030
- 2.3 Segment Snapshot, 2024

### 3. CHEMOTHERAPY INDUCED NEUTROPENIA THERAPEUTICS MARKET- STRATEGIC ANALYSIS REVIEW

- 3.1 Porter's Five Forces Analysis
  - \* Threat of New Entrants
  - \* Threat of Substitutes
  - \* Intensity of Competitive Rivalry
  - \* Bargaining Power of Buyers
  - \* Bargaining Power of Suppliers
- 3.2 Value Chain Analysis
- 3.3 SWOT Analysis

## **4. CHEMOTHERAPY INDUCED NEUTROPENIA THERAPEUTICS MARKET SEGMENTATION ANALYSIS AND OUTLOOK**

### 4.1 Market Segmentation and Scope

### 4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030

#### By Type

Stationary 3D and 4D Ultrasound Devices

Portable 3D and 4D Ultrasound Devices

#### By Display

Color Ultrasound

B/W Ultrasound

#### By Portability

Trolley or Cart-Based Ultrasound Systems

Compact/Handheld Ultrasound Systems

Point-of-Pare (PoC) Ultrasound Systems

#### By Application

Radiology or General Imaging

Obstetrics or Gynecology

Cardiology

Urology

Vascular

Orthopedic and Musculoskeletal

Pain Management

Others

#### By End-User

Hospitals

Surgical Centers and Diagnostic Centers

Maternity Centers

Ambulatory Care Centers

Research and Academia

Others

### 4.3 Growth Prospects and Niche Opportunities, 2023- 2030

### 4.4 Regional comparison of Market Growth, CAGR, 2023-2030

## **5. REGION-WISE MARKET OUTLOOK TO 2030**

### 5.1 Key Findings for Asia Pacific Chemotherapy induced Neutropenia Therapeutics Market, 2025

### 5.2 Asia Pacific Chemotherapy induced Neutropenia Therapeutics Market Size Outlook

by Type, 2021- 2030

5.3 Asia Pacific Chemotherapy induced Neutropenia Therapeutics Market Size Outlook by Application, 2021- 2030

5.4 Key Findings for Europe Chemotherapy induced Neutropenia Therapeutics Market, 2025

5.5 Europe Chemotherapy induced Neutropenia Therapeutics Market Size Outlook by Type, 2021- 2030

5.6 Europe Chemotherapy induced Neutropenia Therapeutics Market Size Outlook by Application, 2021- 2030

5.7 Key Findings for North America Chemotherapy induced Neutropenia Therapeutics Market, 2025

5.8 North America Chemotherapy induced Neutropenia Therapeutics Market Size Outlook by Type, 2021- 2030

5.9 North America Chemotherapy induced Neutropenia Therapeutics Market Size Outlook by Application, 2021- 2030

5.10 Key Findings for South America Chemotherapy induced Neutropenia Therapeutics Market, 2025

5.11 South America Pacific Chemotherapy induced Neutropenia Therapeutics Market Size Outlook by Type, 2021- 2030

5.12 South America Chemotherapy induced Neutropenia Therapeutics Market Size Outlook by Application, 2021- 2030

5.13 Key Findings for Middle East and Africa Chemotherapy induced Neutropenia Therapeutics Market, 2025

5.14 Middle East Africa Chemotherapy induced Neutropenia Therapeutics Market Size Outlook by Type, 2021- 2030

5.15 Middle East Africa Chemotherapy induced Neutropenia Therapeutics Market Size Outlook by Application, 2021- 2030

## **6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030**

6.1 US Chemotherapy induced Neutropenia Therapeutics Market Size Outlook and Revenue Growth Forecasts

6.2 US Chemotherapy induced Neutropenia Therapeutics Industry Drivers and Opportunities

6.3 Canada Market Size Outlook and Revenue Growth Forecasts

6.4 Canada Chemotherapy induced Neutropenia Therapeutics Industry Drivers and Opportunities

6.6 Mexico Market Size Outlook and Revenue Growth Forecasts

6.6 Mexico Chemotherapy induced Neutropenia Therapeutics Industry Drivers and

## Opportunities

6.7 Germany Market Size Outlook and Revenue Growth Forecasts

6.8 Germany Chemotherapy induced Neutropenia Therapeutics Industry Drivers and Opportunities

6.9 France Market Size Outlook and Revenue Growth Forecasts

6.10 France Chemotherapy induced Neutropenia Therapeutics Industry Drivers and Opportunities

6.11 UK Market Size Outlook and Revenue Growth Forecasts

6.12 UK Chemotherapy induced Neutropenia Therapeutics Industry Drivers and Opportunities

6.13 Spain Market Size Outlook and Revenue Growth Forecasts

6.14 Spain Chemotherapy induced Neutropenia Therapeutics Industry Drivers and Opportunities

6.16 Italy Market Size Outlook and Revenue Growth Forecasts

6.16 Italy Chemotherapy induced Neutropenia Therapeutics Industry Drivers and Opportunities

6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts

6.18 Rest of Europe Chemotherapy induced Neutropenia Therapeutics Industry Drivers and Opportunities

6.19 China Market Size Outlook and Revenue Growth Forecasts

6.20 China Chemotherapy induced Neutropenia Therapeutics Industry Drivers and Opportunities

6.21 India Market Size Outlook and Revenue Growth Forecasts

6.22 India Chemotherapy induced Neutropenia Therapeutics Industry Drivers and Opportunities

6.23 Japan Market Size Outlook and Revenue Growth Forecasts

6.24 Japan Chemotherapy induced Neutropenia Therapeutics Industry Drivers and Opportunities

6.26 South Korea Market Size Outlook and Revenue Growth Forecasts

6.26 South Korea Chemotherapy induced Neutropenia Therapeutics Industry Drivers and Opportunities

6.27 Australia Market Size Outlook and Revenue Growth Forecasts

6.28 Australia Chemotherapy induced Neutropenia Therapeutics Industry Drivers and Opportunities

6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts

6.30 South East Asia Chemotherapy induced Neutropenia Therapeutics Industry Drivers and Opportunities

6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts

6.32 Rest of Asia Pacific Chemotherapy induced Neutropenia Therapeutics Industry

## Drivers and Opportunities

6.33 Brazil Market Size Outlook and Revenue Growth Forecasts

6.34 Brazil Chemotherapy induced Neutropenia Therapeutics Industry Drivers and Opportunities

6.36 Argentina Market Size Outlook and Revenue Growth Forecasts

6.36 Argentina Chemotherapy induced Neutropenia Therapeutics Industry Drivers and Opportunities

6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts

6.38 Rest of South America Chemotherapy induced Neutropenia Therapeutics Industry Drivers and Opportunities

6.39 Middle East Market Size Outlook and Revenue Growth Forecasts

6.40 Middle East Chemotherapy induced Neutropenia Therapeutics Industry Drivers and Opportunities

6.41 Africa Market Size Outlook and Revenue Growth Forecasts

6.42 Africa Chemotherapy induced Neutropenia Therapeutics Industry Drivers and Opportunities

## **7. CHEMOTHERAPY INDUCED NEUTROPENIA THERAPEUTICS MARKET OUTLOOK ACROSS SCENARIOS**

7.1 Low Growth Case

7.2 Reference Growth Case

7.3 High Growth Case

## **8. CHEMOTHERAPY INDUCED NEUTROPENIA THERAPEUTICS COMPANY PROFILES**

8.1 Profiles of Leading Chemotherapy induced Neutropenia Therapeutics Companies in the Market

8.2 Business Descriptions, SWOT Analysis, and Growth Strategies

8.3 Financial Performance and Key Metrics

AbbVie Inc

Aurobindo Pharma

BeyondSpring Pharmaceuticals Inc

Coherus BioSciences

G1 Therapeutics Inc

GlaxoSmithKline PLC

Lupin

Merck & Co. Inc

Novartis AG  
Spectrum Pharmaceuticals  
Teva Pharmaceuticals Industries Ltd

## **9. APPENDIX**

- 9.1 Scope of the Report
- 9.2 Research Methodology and Data Sources
- 9.3 Glossary of Terms
- 9.4 Market Definitions
- 9.5 Contact Information



## I would like to order

Product name: Chemotherapy-induced Neutropenia Therapeutics Market Size, Trends, Analysis, and Outlook By Type (Antibiotic Therapy, Granulocyte Colony-Stimulating Factor Therapy, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), by Region, Country, Segment, and Companies, 2024-2030

Product link: <https://marketpublishers.com/r/C08C3FA7E66CEN.html>

Price: US\$ 3,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C08C3FA7E66CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970